Healthcare Services Group, Inc. — Q3 2023 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2023. Financial statements are unaudited. The company provides housekeeping, laundry, linen, facility maintenance, and dietary services to healthcare facilities, primarily long-term-care providers, through Housekeeping and Dietary segments.
Financial performance
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $411.4 million | $414.5 million | $1,247.5 million | $1,266.2 million |
| Income (loss) before tax | $(7.0) million | $1.0 million | $22.0 million | $25.0 million |
| Net income (loss) | $(5.5) million | $0.3 million | $15.8 million | $18.5 million |
| Diluted earnings (loss) per share | $(0.07) | $0.00 | $0.21 | $0.25 |
| Operating cash flow | Not provided for quarter | Not provided for quarter | $(5.9) million | $(31.1) million |
- Q3 revenue fell 0.7% year over year. Costs of services were 91.8% of revenue versus 90.9%; SG&A was 9.5% versus 8.6%. Net margin was approximately negative 1.3%, compared with positive 0.1%.
- Nine-month revenue declined 1.5%; net income declined 14.5%. Costs of services improved to 88.7% of revenue from 89.2%, but SG&A rose to 9.7% from 8.0%. Net margin was approximately 1.3% versus 1.5%.
- Housekeeping revenue declined 3.1% in Q3 and 3.8% year to date, primarily reflecting fewer facilities served. Dietary revenue rose 1.3% in Q3 and 0.6% year to date, supported by contractual pass-through of labor and food costs.
- Q3 Housekeeping segment pretax income declined to $10.3 million from $17.5 million; Dietary reported $1.9 million versus a $0.4 million loss. For nine months, Housekeeping pretax income was $46.9 million versus $55.8 million, while Dietary increased to $29.0 million from $19.3 million.
Liquidity, balance sheet, and cash flow
- At September 30, cash and cash equivalents were $31.3 million and marketable securities were $90.0 million. Working capital was $345.6 million; the current ratio was 2.8, unchanged from year-end 2022.
- Accounts and notes receivable, net, were $396.6 million, up from $369.4 million at December 31, 2022. The allowance for doubtful accounts increased to $90.5 million from $73.5 million.
- Nine-month operating cash use improved to $5.9 million from $31.1 million, but remained negative, mainly due to increased receivables and payment timing. Investing used $1.9 million; financing provided $12.9 million, including $20.0 million of additional line-of-credit borrowings.
- Line-of-credit borrowings were $45.0 million, up from $25.0 million at year-end. The $300 million facility had $169.3 million available after $85.7 million of standby letters of credit. The company was in compliance with its financial covenants; funded debt/EBITDA was 1.49 against a maximum of 3.50, and EBITDA/interest was 9.47 against a minimum of 3.00.
- The board suspended the quarterly dividend in February 2023 and authorized share repurchases. The company repurchased 0.5 million shares for $6.2 million during the nine months, including 0.3 million shares for $4.0 million in Q3. Capital expenditures were $4.0 million through September; management estimated full-year 2023 spending of $4.0–$6.0 million.
Material developments, outlook, and risks
- A Q3 change in estimate for price concessions tied to a client’s out-of-court restructuring reduced revenue by $12.6 million. The filing says the company currently plans to continue providing services under that arrangement.
- A customer group entered bankruptcy in Q3, increasing bad-debt provision by $9.1 million. For the nine months, two customer groups’ deteriorating credit profiles increased bad-debt expense by $13.8 million. Genesis Healthcare contributed 11.1% of Q3 revenue and 11.3% of nine-month revenue; the company cautions that a loss of, or delayed payment from, this customer could materially affect results and cash flow.
- Management cited persistent inflation, labor shortages and wage growth, below-target nursing-home occupancy, and higher labor, supply, and operating costs. The company’s ability to improve performance depends in part on winning and retaining customers, obtaining modest price increases, controlling costs, and developing management personnel.
- Management said existing cash, operating cash flows, and credit capacity should meet foreseeable needs and expects to remain covenant-compliant. No specific earnings or revenue guidance was provided. The ERC claim filed in Q2 had produced no refund or IRS correspondence through October 27, 2023; no credit was recognized because receipt was not considered reasonably assured.
- Risks include customer credit and collections, reliance on Medicare and Medicaid reimbursement at customers, labor and supply inflation, regulatory changes, insurance claims, and interest-rate exposure. Certain litigation losses cannot currently be reasonably estimated. Management reported no material change to the Form 10-K risk factors and no subsequent event requiring disclosure.
Important facts for investors to verify
- Whether the restructuring-related $12.6 million concession and bankruptcy-related credit losses are substantially resolved, and whether receivables and reserves continue to grow.
- Cash collection trends and the drivers of negative year-to-date operating cash flow.
- Customer retention and facility counts, especially at Genesis and in Housekeeping, and whether Dietary cost pass-throughs remain sufficient to protect margins.
- Progress on labor, supply, and SG&A cost control; covenant headroom and borrowing costs; and execution of the stated capital-expenditure estimate.
- Any IRS action or refund related to the ERC claim, and developments in legal, tax, or insurance contingencies that could change reported results.